Share of U.S. adults who favor requiring Medicare to cover the costs of FDA approved drugs and therapies that can slow the progression of Alzheimer's disease as of 2023
Characteristic
Percentage of respondents
Strongly favor
77%
Not so strongly favor
10%
Not so strongly oppose
3%
Strongly oppose
1%
Don't know
8%
The chart is not accessible to screen readers. Please switch to the table view to access the data.
Original question: "Do you favor or oppose requiring Medicare to cover the costs of FDA approved
drugs and therapies that can slow the progression of Alzheimer's
disease?"
Missing percentage points to 100 percent are probably due to rounding.
Citation formats
Share of U.S. adults who favor Medicare covering the cost of Alzheimer's drugs 2023
A survey of U.S. adults from 2023 found that 77 percent strongly favored requiring Medicare to cover the costs of FDA approved drugs and therapies that can slow the progression of Alzheimer's disease. This statistic displays the share of U.S. adults who favor requiring Medicare to cover the costs of FDA approved drugs and therapies that can slow the progression of Alzheimer's disease.
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how ÌÇÐÄÆƽâ°æ can support your business.
Lake Research Partners, & Public Opinion Strategies. (May 22, 2023). Share of U.S. adults who favor requiring Medicare to cover the costs of FDA approved drugs and therapies that can slow the progression of Alzheimer's disease as of 2023 [Graph]. In ÌÇÐÄÆƽâ°æ. Retrieved August 05, 2026, from /statistics/1440197/adults-who-favor-medicare-covering-the-cost-of-alzheimers-drugs/
Lake Research Partners, und Public Opinion Strategies. "Share of U.S. adults who favor requiring Medicare to cover the costs of FDA approved drugs and therapies that can slow the progression of Alzheimer's disease as of 2023." Chart. May 22, 2023. ÌÇÐÄÆƽâ°æ. Accessed August 05, 2026. /statistics/1440197/adults-who-favor-medicare-covering-the-cost-of-alzheimers-drugs/
Lake Research Partners, Public Opinion Strategies. (2023). Share of U.S. adults who favor requiring Medicare to cover the costs of FDA approved drugs and therapies that can slow the progression of Alzheimer's disease as of 2023. ÌÇÐÄÆƽâ°æ. ÌÇÐÄÆƽâ°æ Inc.. Accessed: August 05, 2026. /statistics/1440197/adults-who-favor-medicare-covering-the-cost-of-alzheimers-drugs/
Lake Research Partners, and Public Opinion Strategies. "Share of U.S. Adults Who Favor Requiring Medicare to Cover The Costs of Fda Approved Drugs and Therapies That Can Slow The Progression of Alzheimer's Disease as of 2023." ÌÇÐÄÆƽâ°æ, ÌÇÐÄÆƽâ°æ Inc., 22 May 2023, /statistics/1440197/adults-who-favor-medicare-covering-the-cost-of-alzheimers-drugs/
Lake Research Partners & Public Opinion Strategies, Share of U.S. adults who favor requiring Medicare to cover the costs of FDA approved drugs and therapies that can slow the progression of Alzheimer's disease as of 2023 ÌÇÐÄÆƽâ°æ, /statistics/1440197/adults-who-favor-medicare-covering-the-cost-of-alzheimers-drugs/ (last visited August 05, 2026)
Share of U.S. adults who favor requiring Medicare to cover the costs of FDA approved drugs and therapies that can slow the progression of Alzheimer's disease as of 2023 [Graph], Lake Research Partners, & Public Opinion Strategies, May 22, 2023. [Online]. Available: /statistics/1440197/adults-who-favor-medicare-covering-the-cost-of-alzheimers-drugs/
